Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (STRIDE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00790517|
Recruitment Status : Completed
First Posted : November 13, 2008
Last Update Posted : March 17, 2015
The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications. We will examine the effectiveness of the intervention in
- reducing weight and Body Mass Index;
- reducing fasting insulin levels and increasing insulin sensitivity; and
- reducing total cholesterol and LDL cholesterol.
|Condition or disease||Intervention/treatment||Phase|
|Weight Loss Diabetes Mellitus, Type 2 Psychotic Disorders||Behavioral: Premier Lifestyle Intervention with DASH Diet||Phase 2|
Overweight and obesity are among the leading causes of preventable deaths in the US, primarily through their effects on Type II diabetes mellitus and other cardiovascular disease risk factors. Individuals with serious mental illness represent a large underserved population at greatly increased risk of obesity, diabetes, metabolic syndrome, and subsequent early mortality. These risks are amplified by the antipsychotic agents that are often prescribed to treat these mental conditions.
Although strong evidence indicates that lifestyle interventions are effective at reducing weight and other diabetes risk factors in general populations, and pilot and feasibility studies suggest that such interventions will be effective with individuals who have mental illnesses, no large-scale translational trials have examined such interventions in this population.
STRIDE is a randomized controlled trial to examine the effectiveness, in a mentally ill population, of a lifestyle intervention previously shown to be effective for reducing weight and diabetes risk factors. We target a group of individuals taking antipsychotic agents (n = 280) who receive treatment in one of two clinical settings-a publicly funded behavioral health care clinic and a non-profit private health plan. Counselors from each clinical setting will be trained in the intervention and paired with study staff to deliver it, increasing generalizability, and improving the probability of future adoption. The intervention promotes moderate calorie reduction, dietary changes, and increased energy expenditure, and is based on current clinical practice guidelines for treating obesity and cardiovascular disease.
Specific aims test the hypotheses that the intervention is more effective than usual care in: 1) reducing weight and Body Mass Index; 2) reducing fasting insulin levels and increasing insulin sensitivity; and 3) reducing total cholesterol and LDL cholesterol. A fourth aim explores effects of motivation, social support, and outcomes expectancies on primary outcomes, and moderators of intervention effectiveness (ethnicity, gender, mental illness diagnostic group, medication type, metabolic syndrome) on outcomes.
Implementation and process evaluations will assess the fidelity of intervention delivery, evaluate its acceptability; identify components participants find most and least helpful; identify barriers to, and facilitators of, lifestyle changes; and evaluate the effects of the intervention on body image, psychiatric symptoms, adherence to antipsychotic medications, quality of life, health-related self-efficacy, health, functional status, and social support. Cost-effectiveness analyses will evaluate incremental costs of producing change in each primary outcome (weight, BMI, fasting insulin levels, insulin sensitivity, and cholesterol).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Reducing Weight and Diabetes Risk in an Underserved Population|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||December 2014|
Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
Behavioral: Premier Lifestyle Intervention with DASH Diet
Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
Other Name: DASH Diet
No Intervention: 2
- Body Mass Index [ Time Frame: 6, 12, 24 months ]
- Weight [ Time Frame: 6, 12, 24 months ]
- Insulin sensitivity [ Time Frame: 6, 12, 24 months ]
- Fasting insulin levels [ Time Frame: 6, 12, 24 months ]
- Cholesterol levels [ Time Frame: 6, 12, 24 months ]
- Body Image [ Time Frame: 6, 12, 24 months ]
- Antipsychotic Medication Adherence [ Time Frame: 6, 12, 24 months ]
- Psychiatric Symptoms [ Time Frame: 6, 12, 24 months ]
- Health-related self-efficacy [ Time Frame: 6, 12, 24 months ]
- Social support for diet/weight loss [ Time Frame: 6, 12, 24 months ]
- Quality of life [ Time Frame: 6, 12, 24 months ]
- Health/functional status [ Time Frame: 6, 12, 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00790517
|United States, Oregon|
|Cascadia Behavioral Healthcare|
|Portland, Oregon, United States, 97207|
|Center for Health Research, Kaiser Permanente Northwest|
|Portland, Oregon, United States, 97227-1110|
|Portland, Oregon, United States, 97229|
|Principal Investigator:||Carla A Green, PhD, MPH||Center for Health Research, Kaiser Permanente Northwest|